Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Key claim: A clinical trial is comparing the efficacy and safety of givinostat (an HDAC inhibitor) versus hydroxyurea in JAK2V617F-positive high-risk polycythemia vera patients.
Abstract
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
Why this matters
Frontline cytoreduction in high-risk PV is being actively redefined: alongside MITHRIDATE’s three-way comparison of ruxolitinib, hydroxycarbamide, and interferon, this givinostat vs hydroxyurea trial introduces a mechanistically distinct HDAC inhibitor as a direct challenger to standard of care in JAK2V617F-positive disease. Together these trials signal a shift from hydroxyurea monopoly toward subtype- and mutation-specific frontline strategies in PV.